Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The HD-MAP seasonal influenza vaccine is a needle-free, quadrivalent inactivated influenza vaccine (IIV4) delivered via Vaxxas' proprietary High-Density Microarray Patch (HD-MAP) technology. The patch consists of an ultra-high-density array of micro-projections that deliver split inactivated influenza virus antigens directly to the immune-cell-rich layers of the skin. This delivery method is designed to enhance immunogenicity compared to traditional intramuscular injection while offering advantages such as thermostability (stable at 40°C for 12 months) and the potential for self-administration. The vaccine targets four strains of influenza (two A and two B) and is currently in Phase I clinical development for the prevention of seasonal influenza in healthy adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HD-MAP seasonal influenza vaccine.